ArticleInternational journal of general medicine2022
miR-873 and miR-105-2 May Affect the Tumour Microenvironment and are Potential Biomarkers for Lung Adenocarcinoma.
Article in International journal of general medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 9 citations in OpenAlex.
- A high stroma-tumor ratio is associated with an immunosuppressive tumor microenvironment and a poor prognosis in bladder cancer.Frontiers in oncology · 2025Article
- MiR-4664-3p as a potential diagnostic, prognostic, and immunotherapeutic biomarker in NSCLC: modulation of tumor progression through CD8 + T cell regulation.Frontiers in oncology · 2025Article
- CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer.Scientific reports · 2024Article
- IAPP blocks anti-breast cancer function of CD8Frontiers in immunology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) accounts for approximately 40% of all lung cancer cases. The tumour microenvironment (TME) and microRNAs affect the occurrence, metastasis, recurrence and treatment of tumours. However, the role of microRNAs in the TME and LUAD still needs to be further investigated. Methods: RNA-seq and microRNA-seq data of LUAD and NSCLC samples were downloaded from the TCGA and GEO database. The immune and stromal components in the TME and the abundance of tumour-infiltrating immune cells (TICs) were calculated by the ESTIMATE and CIBERSORT algorithms, respectively. The differentially expressed microRNAs (DEMs) between different StromalScore and ImmuneScore groups were screened out by the edgeR package. Bioinformatics analysis was performed to screen out important DEMs and explore their functional effect. Results: Our results revealed that a low StromalScore, ImmuneScore and ESTIMATEScore led to poor prognosis of LUAD. Then, 62 DEMs were screened out as downregulated in both the high StromalScore and ImmuneScore groups. Among these DEMs, elevated expression levels of miR-873, miR-105-2 and miR-516a-2 significantly shortened the survival time of LUAD patients. Subsequent analysis revealed that the expression levels of miR-873 and miR-105-2 were increased significantly in tumour tissues. The expression patterns of these 2 microRNAs were confirmed by GSE102286, implying the important roles of these 2 microRNAs in LUAD. Further analysis showed that miR-873 and miR-105-2 were mainly involved in immune-related pathways and that high expression levels of miR-873 and miR-105-2 decreased the abundance of monocytes and resting dendritic cells in the TME. Conclusion: Although further exploration is still needed, our results revealed that miR-873 and miR-105-2 were closely related to the TME and affected the prognosis of LUAD by altering the abundance of TICs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.